Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider
- 5 May 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (7) , 1842-1848
- https://doi.org/10.1093/ndt/gfh280
Abstract
End-stage renal disease (ESRD) patients are prescribed numerous medications. The United States Renal Data System (USRDS) reported on medication prescribing patterns in 1998. Since then, several new medications, treatment guidelines and recommendations have been introduced. The objective was to analyse and compare haemodialysis (HD) patient medication prescribing patterns between the Dialysis Clinic, Inc. (DCI) database and the USRDS report. Point-prevalent (01/01/03) medication use data from the DCI national database was obtained. Data collected included patient demographics, reason for and duration of ESRD, and medication listed on profile. All medications were classified similar to the USRDS and by where taken (clinic vs home). Medication prescribing patterns were compared between DCI and USRDS databases. Comparisons between age groups (or=65 years) and diabetic status [diabetes mellitus (DM) vs non-DM] were made. There were 128 477 medication orders categorized in 10 474 patients. DCI patient demographics were similar to present USRDS patients except for fewer Hispanics (P<0.001). Patients were prescribed 12.3+/-5.0 (median 12) different medications (2.6+/-1.4 clinic medications and 10.0+/-4.5 home medications). This is higher than reported by USRDS (median 9 medications). Patient age did not influence number of medications used (P = 0.54). DM patients are prescribed more medications than non-DM (13.3+/-5.0 DM vs 11.6+/-4.8 non-DM; P<0.00001). All medication class prescribing patterns were markedly different. The data suggest that medication prescribing patterns in HD patients have changed. The audit identified appropriate and questionable prescribing patterns. Various prescribing patterns identified areas for improvement in care (e.g. increased use of aspirin, beta-blockers and hyperlipidaemia medications) and areas requiring further investigation (e.g. high use of anti-acid, benzodiazepine and non-aluminum/non-calcium phosphate-binding medications).Keywords
This publication has 14 references indexed in Scilit:
- Information for contributorsAmerican Journal of Kidney Diseases, 2003
- Drug Record Discrepancies in an Outpatient Electronic Medical Record: Frequency, Type, and Potential Impact on Patient Care at a Hemodialysis CenterPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Factors associated with medication-related problems in ambulatory hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney diseaseAmerican Heart Journal, 2002
- Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and EuropeKidney International, 2002
- Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in managementAmerican Journal of Kidney Diseases, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Comparing medication use in two hemodialysis units against national dialysis databasesAmerican Journal of Health-System Pharmacy, 2000
- Epidemiology of Cardiac Disease in Dialysis PatientsSeminars in Dialysis, 1999
- Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular DiseaseAmerican Journal of Kidney Diseases, 1998